Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Gary L. Kepler who wrote (8979)	10/25/2001 2:19:36 PM
From: Vector1	Read Replies (1) \| Respond to of 9719

Thanks Gary, I saw the comments on CALP/MLNM on one of the other threads. I do not think there is much overlap between AFFX and CALP. AFFX at its core allows for high density comparisons at low cost and is a very powerful platform. CALPs technolgy allows for "wet' science to be conducted on microsized chips with little use of expensive reagents and the opportunity for high speed using robotics. A company like MLNM, or any major research and development organization will need some version of both to be competitive in the future. One of the important elements for AFFX of the MLNM deal is that MLNM was experimenting number of technologies (including its own chips) that are competive with AFFX and ultimately must have decided that even though they are expensive the AFFX chips and their patent portfolio caried the day. AFFX also reported excellent earnings. An excerpt from the JP Morgan report * Importantly, the main revenue drivers was Affymetrix' core GeneChip products. Chip volume was approximately 70,000 (excluding the 10,000 replacement murine chips), or a 50% increase over Q3/00. The company shipped approximately four GeneChip systems per week in Q3 (slightly higher than its recent 3/week pace). (snip) * We continue with our Buy rating and expect the stock to trade into the high 20's as investors continue to regain confidence in AFFX. This quarter the company demonstrated that the DNA chip market is not stagnating, competition is not winning over key accounts and GeneChip are being deployed in areas outside of early stage drug target discovery (snip) V1